Active, Not Recruiting
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors - CA022-001
Aktualizováno: 2 leden, 2024 | ClinicalTrials.gov
Fáze
Pohlaví
Věková skupina
Active, Not Recruiting
Inclusion Criteria: - For more information regarding Bristol Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com - histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable) - Eastern Cooperative Oncology Group Performance Status of 0 or 1 - Participants must have received, and then progressed, relapsed, or been intolerant to, all standard treatment regimens with proven survival benefit in the advanced or metastatic setting according to tumor type, if such a therapy exists Exclusion Criteria: - Participants with primary CNS malignancies, or tumors with CNS metastases as the only site of disease, will be excluded - Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy - Prior anti-cancer treatments such as chemotherapy, radiotherapy, hormonal, or immunotherapy (including anti-PD-1/PD-L1) are permitted Other protocol defined inclusion/exclusion criteria could apply
Důrazně doporučujeme kontaktovat BMS a oznámit vedlejší účinky / nežádoucí příhody
Zde jsou definovány vedlejší účinky / nežádoucí příhody a další příhody, které by měly být hlášeny
Nahlásit vedlejší účinky / nežádoucí příhody nebo stížnosti na kvalitu produktu: lékařské informace
